12Feb/14

FDA looks at possible heart failure link with AZ's Onglyza – PharmaTimes


Drug Discovery & Development

FDA looks at possible heart failure link with AZ’s Onglyza
PharmaTimes
The agency will review Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin/metformin) after a study published in the New England Journal of Medicine reported an increased rate of hospitalisation for heart failure with use of the drugs. The FDA …
FDA Investigating Heart Failure Risk Linked To OnglyzaForbes
FDA to probe saxagliptin’s heart failure riskFamily Practice News Digital Network
FDA Investigating Heart Failure Risks with SaxagliptinDrug Discovery & Development
HealthDay
all 34 news articles »
12Feb/14

Revealed – the biological 'switch' that causes fatty liver disease – India.Com Health


India.Com Health

Revealed – the biological ‘switch’ that causes fatty liver disease
India.Com Health
Liver disease In major find, scientists have discovered a biological switch that regulates a protein that causes fatty liver disease. ‘We have learned how the body finely tunes levels of a protein called SCAP that is required to turn on fat production …

and more »